ArticleJournal of general and family medicine2026
Nocturnal BiPAP Therapy Improved Chronic Respiratory Failure in Chilaiditi Syndrome.
Article in Journal of general and family medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nocturnal BiPAP Therapy Improved Chronic Respiratory Failure in Chilaiditi Syndrome.Journal of general and family medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chilaiditi syndrome includes the Chilaiditi sign, a radiological finding where a segment of bowel loop or small intestine has wandered between the liver and diaphragm and also any symptoms related to intestinal interference. Case Presentation: We report the case of a 79-year-old man with Chilaiditi syndrome whose dyspnea and sleep disturbance improved after nocturnal biphasic positive airway pressure (BiPAP) therapy implementation. Discussion: BiPAP therapy may contribute to thoracic pressure elevation and reduce diaphragmatic compression due to intestinal enlargement, thus leading to improvements in respiratory symptoms. Conclusion: BiPAP therapy should therefore be considered as a treatment option for Chilaiditi syndrome patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.